Release Date: 23-Feb-2023
The process of drug delivery and development is filled with high-risk and stakes with a course of long and costly timelines. Despite these pitiable probabilities, the possibility of driving and leading a billion dollar market, the pharmaceutical market has started to diversify their drug discovery process. Transforming from conventional strategies and moving to modification of druggable protein targets has been successful in bringing now entities and targets in the industry.
Download Report: https://www.kuickresearch.com/report-syk-inhibitors-fostamatinib-market-sales-forecast-clinical-trials
One such emerging protein target is Spleen tyrosine Kinase (SYK). Being involved in immuno receptor signaling of variety of cell types, targeting of this protein has shown to have a potential therapeutic effect. Subsequently, the pharmaceutical industry has begun its journey to discover and discern the approach of developing spleen Tyrosine Kinase inhibitors. Several, pre-clinical and clinical studies have been conducted in order to define the therapeutic potential of Spleen Tyrosine kinase inhibitors.
SYK inhibitors have opened a promising new class of drugs that are revolutionizing the way we treat a variety of disorders, including cancer, inflammatory diseases and autoimmune diseases. There remains only one US FDA approved Spleen Tyrosine Kinase inhibitor, Fostamatinib (TAVALISSE) developed by Rigel Pharmaceuticals for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Earlier the US FDA had granted this application standard review and orphan drug designation. The approval was based on two identical, double-blind, placebo-controlled trials, Efficacy were based on stable platelet response. Although targeting a minor populating, the drug has witnessed success in this market region. During Q3 of 2022, TAVALISSE net product sales were more than US$50 Million, representing the highest net product sales since the launch an increase of more than 10% compared to the same period of 2021, as per Rigel’s quarterly report.
One of the major benefiting factors of Spleen Tyrosine Kinase inhibitors is their ability to target multiple pathways involved in disease pathogenesis. For instance, SYK inhibitors can disrupt the tumor microenvironment leading to reduced tumor growth and increased sensitivity to cancer treatments. Another important factor is their excellent safety profile, with minimal adverse effects reported in clinical trials, making them an attractive treatment option for patients who are unable to tolerate other therapies or have limited treatment options available.
The pharmaceutical industry seems excited about the potential of SYK inhibitors to transform the treatment landscape of several disorders. The development of SYK inhibitors can be considered a major breakthrough in the treatment of several major diseases. With its unique ability to target multiple pathways, SYK offers the potential for more effective and personalized therapies for patients. This targeted approach has the potential to minimize off-target effects and reduce the risk of adverse effects making them a safer and effective treatment option.
Additionally, the use of SYK inhibitors in combinational therapies is also being investigated in several clinical trials. As continuous advancements are witnessed in the field of SYK inhibitors, the pharmaceutical industry has started streamlining their research and development pipelines in order to test their novel SYK inhibitors. For instance, Kronos Bio has prioritized its clinical portfolio to focus on the development of its next generation Spleen Tyrosine Kinase Inhibitor, Ianraplenib.
This report aims to provide an in-depth analysis about the recent market trends ad clinical progress made in the field of spleen tyrosine kinase inhibitors. Moreover, the market growth and penetration of the only approved drug in this market segment is also discussed in this report. There are several key players that are ready to set foot in this emerging market of SYK inhibitors, some of which are. Our report highlights the key strategies adopted by these companies in order to maintain their pace in the Spleen Tyrosine Kinase targeted therapy market.